Loading cancer entity…
Loading cancer entity…
Clinical trials
195 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (19)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 |
| clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05472948 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Oct 2, 2023 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials